Three Good Reasons Why An Integrated CDMO Model Offers The Best Route To Success

Source: Pfizer CentreOne

Although commercialization routes for drugs and therapeutic compounds are relatively well mapped, the drug development and manufacturing process will always require experienced navigation skills to anticipate challenges. It takes expertise to keep projects on course to target markets. That’s why the outsourcing of drug product development and manufacturing with contract suppliers has become the preferred go-to-market strategy by many of the industry’s leading drug developers and intellectual property (IP) owners.

As demand for strategic outsourcing grows more powerful, so have the offerings of contract development and manufacturing organizations (CDMOs). Some of pharma’s top legacy brands also took notice of the market’s potential and developed their own innovative response.

What emerged is a distinct class of contract development and manufacturing services suppliers (similar to contemporary end-to-end CDMOs) but immersed in big pharma.

Learn more about three good reasons why an integrated CDMO can offer the best route to commercial success.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Biosimilar Development